stoxline Quote Chart Rank Option Currency Glossary
  
Vaxart, Inc. (VXRT)
1.27  -0.13 (-9.29%)    02-23 16:00
Open: 1.41
High: 1.43
Volume: 2,345,774
  
Pre. Close: 1.4
Low: 1.24
Market Cap: 214(M)
Technical analysis
2024-02-23 4:40:20 PM
Short term     
Mid term     
Targets 6-month :  1.79 1-year :  2.1
Resists First :  1.53 Second :  1.79
Pivot price 1.22
Supports First :  1.03 Second :  0.72
MAs MA(5) :  1.3 MA(20) :  1.17
MA(100) :  0.78 MA(250) :  0.81
MACD MACD :  0.1 Signal :  0.1
%K %D K(14,3) :  67.1 D(3) :  74.7
RSI RSI(14): 64.3
52-week High :  1.59 Low :  0.52
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ VXRT ] has closed below upper band by 36.3%. Bollinger Bands are 33% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.43 - 1.44 1.44 - 1.45
Low: 1.22 - 1.23 1.23 - 1.24
Close: 1.26 - 1.27 1.27 - 1.28
Company Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Headline News

Fri, 23 Feb 2024
5 Top-Ranked Stocks That Have More Than Doubled Year to Date - Yahoo Finance

Thu, 22 Feb 2024
Do Traders Think Vaxart Inc (VXRT) Can Keep Climbing Thursday? - InvestorsObserver

Thu, 22 Feb 2024
Investors in Vaxart (NASDAQ:VXRT) from three years ago are still down 81%, even after 19% gain this past week - Simply Wall St

Tue, 20 Feb 2024
Is Vaxart Inc (VXRT) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Tue, 20 Feb 2024
VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research

Thu, 15 Feb 2024
Vaxart Regains Compliance with Nasdaq Listing Standards - TipRanks.com - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 153 (M)
Shares Float 137 (M)
Held by Insiders 0.7 (%)
Held by Institutions 18.6 (%)
Shares Short 11,110 (K)
Shares Short P.Month 11,790 (K)
Stock Financials
EPS -0.63
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.46
Profit Margin 0 %
Operating Margin -848.3 %
Return on Assets (ttm) -41.6 %
Return on Equity (ttm) -91.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.02
EBITDA (p.s.) -0.56
Qtrly Earnings Growth 0 %
Operating Cash Flow -86 (M)
Levered Free Cash Flow -85 (M)
Stock Valuations
PE Ratio -2.02
PEG Ratio 0
Price to Book value 2.7
Price to Sales 46.83
Price to Cash Flow -2.27
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2023-12-19
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android